Natera (NASDAQ: NTRA) reported Q1 EPS of ($0.70), $0.06 worse than the analyst estimate of ($0.64). Revenue for the quarter came in at $46.9 million versus the consensus estimate of $42.81 million.

GUIDANCE:

Natera sees Q2 2017 revenue of $210-230 million, versus the consensus of $218.6 million.

2017 Financial Outlook

Natera anticipates 2017 total revenues of $210 million to $230 million; 2017 cost of product revenues to be approximately 60% to 65% of revenues; selling, general and administrative costs to be approximately $135 million to $140 million; research and development costs to be $45 million to $50 million, and net cash burn to be $65 million to $75 million**. This forecast improves Natera's previously provided financial outlook by reducing cash burn expectations by $10 million. Natera's research and development investments are intended to enhance its service offering and reduce the cost of goods sold of Panorama and Horizon, as well as technology development, product development, and clinical trials within oncology. Consistent with this guidance, Natera anticipates revenues and gross margins to increase, and cash burn to decrease, in the second quarter 2017 and through the remainder of 2017.

For earnings history and earnings-related data on Natera (NTRA) click here.